Aimmune Therapeutics, Inc.
BiotechAimmune Therapeutics, Inc. is a biotechnology company focused on Immunology, Dermatology.
Aimmune Therapeutics, Inc. at a Glance
- Strong track record with 84% execution quality across 11 trials
- Fast trial execution (23 months median completion)
Aimmune Therapeutics, Inc.'s Key Drugs
Aimmune Therapeutics, Inc.'s core commercial portfolio centers on Vowst, spanning Immunology and Dermatology — its most strategically important drugs approved in the last 15 years.
Aimmune Therapeutics, Inc.'s Recent FDA Approvals
New NDA/BLA approvals for Aimmune Therapeutics, Inc. over the last two years — novel drugs only, excluding generics and label supplements.
Aimmune Therapeutics, Inc.'s Therapeutic Areas
Aimmune Therapeutics, Inc.'s approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Aimmune Therapeutics, Inc.'s Top Competitors
Aimmune Therapeutics, Inc.'s closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Aimmune Therapeutics, Inc. Pipeline Snapshot
Aimmune Therapeutics, Inc. has 15 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 8 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Vowst leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 7/8 completed
- • Speed: 23 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-04-25
- Latest
- 2023-04-25
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges